On April 3, 2023, the U.S. Food and Drug Administration approved enfortumab vedontin-ejfv with pembrolizumab for patients with locally advanced…
On March 29, 2023, the U.S. Food and Drug Administration approved pembrolizumab for adult and pediatric patients with unresectable or…
By Dr. Shipra Gandhi Roswell Park Comprehensive Cancer Center Endocrine therapy is the mainstay of the management of hormone…
On March 22, 2023, the U.S. Food and Drug Administration granted accelerated approval to retifanlimab-dlwr — a humanized monoclonal antibody…
The International Innovation Grant will Fund Research on the Effectiveness of Community Screening Programs for the Early Detection of Oral…
By Dr. Luke Fletcher Willamette Valley Cancer Institute & Research Center The Zuma 7 trial is a randomized, open-label multicenter…
By Dr. Dipesh Uprety Karmanos Cancer Institute
By Dr. Radhika Kulkarni Henry Ford Cancer Institute On March 2nd, 2023, results of the Phase 2 trial, SWOG…
On March 16, 2023, the U.S. Food and Drug Administration approved dabrafenib and trametinib for pediatric patients 1 year of…
By Dr. Dipesh Uprety Karmanos Cancer Institute While immunotherapy is being used religiously for non-oncogene-addicted advanced non-small cell lung…